VHL disease and HIF-2alpha inhibitor
In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, USA speaks about the use of hypoxia-inducible factor (HIF) 2alpha inhibitor for the treatment of renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease. Firstly, Dr Jonasch describes how HIF-2alpha combines with HIF-1beta to act as a transcription factor […]